Literature DB >> 9334834

Lack of involvement of retinoic acid receptor alpha in retinoid-induced skin irritation in hairless mice.

A M Standeven1, M Teng, R A Chandraratna.   

Abstract

It has been proposed that RAR gamma, the major retinoic acid receptor (RAR) subtype in skin, mediates retinoid-induced skin irritation. However, RAR alpha is also found in skin, and its role in retinoid-induced skin irritation has not been tested. In this study, RAR subtype-specific agonists and antagonists were used to test the possible contribution of RAR alpha to retinoid-induced skin irritation. Female hairless mice were treated topically on the dorsal skin for 5 days with various retinoids over a 2-log dose range, and cutaneous toxicity was scored by semiquantitative visual observations of skin flaking and abrasions daily up to 3 days post-treatment. Three RAR alpha-selective agonists were > or = 100-fold less potent as skin irritants than the structurally-related RAR pan-agonist, TTNPB. Skin irritation potency decreased in the following order: TTNPB > > Am580 > AGN 193835 > > 193836 and correlated with RAR beta and/or RAR gamma binding affinity rather than RAR alpha binding affinity. TTNPB-induced skin irritation was blocked in a dose-dependent fashion by co-treatment with the RAR pan-antagonist AGN 193109 but was not blocked by co-treatment with the RAR alpha-specific antagonist AGN 194301. In contrast, skin irritation induced by the RAR alpha-selective agonist AGN 193835 was almost completely blocked by co-treatment with AGN 193644, an RAR beta/gamma-selective antagonist. These data demonstrate that RAR alpha is not significantly involved in mediating retinoid-induced skin irritation in mice and suggest that RAR alpha-selective agonists may have reduced mucocutaneous side effects relative to other retinoids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334834     DOI: 10.1016/s0378-4274(97)00065-9

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  7 in total

Review 1.  Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

Authors:  Hisham Abdel-Azim; Weili Sun; Lingtao Wu
Journal:  Pharmacol Ther       Date:  2019-08-27       Impact factor: 12.310

2.  Regulation of keratin expression by retinoids.

Authors:  Hans Törmä
Journal:  Dermatoendocrinol       Date:  2011-07-01

3.  Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.

Authors:  Doris M Benbrook; Scott A Kamelle; Suresh B Guruswamy; Stan A Lightfoot; Teresa L Rutledge; Natalie S Gould; Bethany N Hannafon; S Terence Dunn; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

4.  Heteroarotinoids with anti-cancer activity against ovarian cancer cells.

Authors:  Thanh C Le; K Darrell Berlin; Stacy D Benson; Margaret A Eastman; Gianna Bell-Eunice; Anna C Nelson; Doris M Benbrook
Journal:  Open Med Chem J       Date:  2007-10-24

5.  Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity.

Authors:  Shijin Yin; Jialie Luo; Aihua Qian; Junhui Du; Qing Yang; Shentai Zhou; Weihua Yu; Guangwei Du; Richard B Clark; Edgar T Walters; Susan M Carlton; Hongzhen Hu
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

6.  Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.

Authors:  Lin Li; Xiaotian Qi; Weili Sun; Hisham Abdel-Azim; Siyue Lou; Hong Zhu; Nemani V Prasadarao; Alice Zhou; Hiroyuki Shimada; Koichi Shudo; Yong-Mi Kim; Sajad Khazal; Qiaojun He; David Warburton; Lingtao Wu
Journal:  EMBO Mol Med       Date:  2016-11-02       Impact factor: 12.137

Review 7.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.